

- 1 **Duration of obesity exposure between ages 10-40 years and its relationship with**
- 2 **cardiometabolic disease risk factors: a cohort study**
- 3 **Running title:** Obesity duration and cardiometabolic disease risk factors

Tom Norris^{1*}, Tim J. Cole²,

26 **Abstract:**

27 **Background:** Individuals with obesity do not represent a homogeneous group in terms of
28 cardio-metabolic risk. Using three nationally representative British birth cohorts, we
29 investigated whether the duration of obesity was related to heterogeneity in cardiometabolic
30 risk.

31 **Methods and Findings:** We used harmonised body mass index and cardiometabolic
32 disease risk factor data from 20 746 participants (49.1% male and 97.2% White British)
33 enrolled in three British birth cohort studies: the 1946 National Survey of Health and

60 **Why Was This Study Done?**

61 People with obesity (body mass index > 30 kg/m²) do not all share the same risk for
62 development of cardiometabolic disease risk factors.

63 The duration a person has spent with obesity over their life course could be one factor
64 contributing to the variation observed in cardiometabolic risk.

65 However, previous studies have been unable to adequately separate the effects of obesity
66 duration (how long a person has been obese) and obesity severity (the magnitude of a
67

68 **What Did the Researchers Do and Find?**

69 We derived body mass index trajectories between 10 and 40 years of age in 20 746
70 participants

129 observing a positive relationship with obesity duration [15,17-23]. The largest of these
130 studies (n=61,821) [21] observed that for each 2-year increment in obesity duration, the risk
131 of type 2 diabetes increased by 14%, though, as observed in other studies [19,22], estimates
132 were attenuated upon adjustment for current weight (representing obesity severity).

194 and 46 years in the 1970 cohort (n=8 581). Measurements of systolic (SBP) and diastolic
195 blood pressure (DBP) were obtained as well as blood cardiometabolic biomarkers (glycated
196 haemoglobin (HbA1c) and high-density lipoprotein cholesterol (HDL-C)). More information
197 about the measurement protocols can be found in S1 Text.

198 **Statistical analysis**

199 TN and WJ determined which analyses to perform and include in the present paper in
200 January 2019 after discussing options with all co-authors. The analysis plan was revised in
201 May (modelling obesity duration as a categorical variable rather than a continuous variable)
202 and October 2019 (removing LDL-cholesterol as an outcome due to high amount of missing
203 data) when further exposure and outcome data were obtained and explored. Further

229 the presence of obesity at any timepoint was identified, representing any BMI z-score which
230 exceeded the obesity threshold. Secondly, the number of times obese was calculated as
231 the -score crossed upwards through the obesity
232 threshold. Thirdly, age first obese was derived, representing the age, in years, when BMI z-
233 score first crossed upwards through the obesity threshold. Total duration of obesity was
234 calculated as the length of time, in years, that -score exceeded the obesity

264 unadjusted for covariates. A subsequent model included adjustments for sex, cohort, birth
265 weight (kg), ethnicity (white vs non-white), social class in childhood
266 reported when the child was 10-
267 Classes schema- see S2 Text for more details)and age at follow-up. A final model also
included an adjustment for

298 Analyses were performed in Stata version 15 (Stata Corp, College Station, TX) and R
299 version 3.5.3 (R Core Team 2019).

300 This study is reported as per the Strengthening the Reporting of Observational Studies in
301 Epidemiology (STROBE) guideline (S1 Checklist).

302 **Code availability**

303 The statistical code for the analyses in this paper has been placed in GitHub, the open-
304 access online repository (repository URL: [https://github.com/tomnorris1988/Obesity-
duration-and-cardiometabolic-outcomes](https://github.com/tomnorris1988/Obesity-
305 duration-and-cardiometabolic-outcomes)).

306 **RESULTS:**

340 There was also a linear trend between obesity duration and risk for elevated HbA1c, with
341 those obese <5 years having a 2.1 (95% CI: 1.8, 2.4) times higher risk of elevated HbA1c of
342 compared to never obese, which more than doubled in those obese for 20-30 years (relative
343 risk 4.6; 95% CI: 3.9, 5.5, $p(\text{trend}) < 0.001$) (Fig 2, right panel). However, upon adjustment for
344 obesity severity, this graded relationship was attenuated ($p(\text{trend}) = 0.006$).

345 SBP and DBP

346 There was a positive relationship between ever being obese between 10-40 years and both
347 systolic and diastolic blood pressure. For example, ever obese was associated with a 6.1%
(95% CI: 5.6, 6.6)

419 independent association of obesity duration with HDL-C is lacking. To our knowledge only
420 one other study has investigated this and observed an association in females only, though
421 the strength of evidence was modest ($p=0.05$) [14].

422 In addition to the cited empirical studies, there is also a plausible biological mechanism
423 supporting the observed association between obesity duration and HbA1c (reflecting
424 impaired glucose metabolism). Obesity is characterised by enlarged fat stores, which results
425 in enhanced lipolysis and an increase in circulating free fatty acids. This state leads to
426 peripheral and hepatic insulin resistance [48,49], resulting in a compensatory insulin
427 hypersecretion by the pancreas β -cells in order to preserve normoglycemia[50]. Prolonged
428 β -cell exhaustion [51], culminating in a reduced insulin response and an
429 inability to maintain normoglycemia [52]. In addition, prolonged obesity may represent a
430 state in which subcutaneous adipose stores have been exhausted, with the consequence
431 being a deposition of adipose tissue around the visceral organs (e.g. liver and pancreas),

454 prevalence of abdominal obesity has increased more in females than in males [56].
455 Furthermore, the prevalence of visceral obesity associated with metabolic syndrome is two
456 to ten times higher in women throughout the world [57 59]. It may be therefore, that
457 compared to males, females are more exposed to this metabolically-volatile adipose tissue
458 and thus at increased risk of its deleterious outcomes.

459 **Strengths**

460 The key strength of our study is the derivation, using over 130 000 serial BMI observations
across the life course, of individualised obesity parameters which enabled us to distinguish

489 analyses limited to the NCDS and BCS cohorts only and replacing the NSHD blood pressure
490 variables with those collected at 43 years, produced similar estimates (S7-S10 Tables).

Associations observed in this study

References

1. Non-

doi:10.1016/j.atherosclerosis.2005.06.016

11. Mongraw-Chaffin M, Foster MC, Kalyani RR, Vaidya D, Burke GL, Woodward M, et al. Obesity severity and duration are associated with incident metabolic syndrome: Evidence against metabolically healthy obesity from the multi-ethnic study of atherosclerosis. *J Clin Endocrinol Metab.* 2016;101: 4117-4124. doi:10.1210/jc.2016-2460
12. The NS, Richardson AS, Gordon-Larsen P. Timing and duration of obesity in relation to diabetes: Findings from an ethnically diverse, nationally representative sample. *Diabetes Care.* 2013;36: 865-872. doi:10.2337/dc12-0536
13. Moran A, Jacobs DR, Steinberger J, Hong CP, Prineas R, Luepker R, et al. Insulin resistance during puberty: Results from clamp studies in 357 children. *Diabetes.* 1999;48: 2039-2044. doi:10.2337/diabetes.48.10.2039
14. Janssen I, Katzmarzyk PT, Ross R. Duration of overweight and metabolic health risk

- simplify the presentation of log transformed data. *Stat Med.* 2000;19: 3109–3125. doi:10.1002/1097-0258(20001130)19:22<3109::AID-SIM558>3.0.CO;2-F
42. Royston P, White I. Multiple Imputation by Chained Equations (MICE): Implementation in Stata. *J Stat Softw.* 2011;45. doi:10.18637/jss.v045.i04
 43. Rubin D. Multiple imputation for nonresponse in surveys. John Wiley & Sons, Ltd; 1987. Available: https://books.google.co.uk/books?hl=en&lr=&id=bQBtw6rx_mUC&oi=fnd&pg=PR24&dq=multiple+imputation+for+nonresponse+in+surveys&ots=8OpM8KZ0hQ&sig=UxYMFHtf1xNVr_m85V6Bmv5jETY
 44. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. *Stat Med.* 2011;30: 377–399. doi:10.1002/sim.4067
 45. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and T of HBC in A (Adult TPI. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation.* 2002;106: 3143–3421. doi:10.1097/00019616-199311000-00022
 46. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care.* 2014;37. doi:10.2337/dc14-S081
 47. Reis JP, Loria CM, Lewis CE, Powell-Wiley TM, Wei GS, Carr JJ, et al. Association between duration of overall and abdominal obesity beginning in young adulthood and coronary artery calcification in middle age. *JAMA - J Am Med Assoc.* 2013;310: 280–288. doi:10.1001/jama.2013.7833
 48. Kissebah AH. Intra-abdominal fat: is it a major factor in developing diabetes and coronary artery disease? *Diabetes Res Clin Pract.* 1996;30 Suppl: 25–30. doi:10.1016/s0168-8227(96)80035-0
 49. Felber JP, Golay A. Pathways from obesity to diabetes. *Int J Obes.* 2002;26: S39–S45. doi:10.1038/sj.ijo.0802126
 50. Investigation. 2006. pp. 1802–1812. doi:10.1172/JCI29103
 51. Groop LC, Eriksson JG. The etiology and pathogenesis of non-insulin-dependent diabetes. *Ann Med.* 1992;24: 483–489. doi:10.3109/07853899209167000
 52. Leahy JL. Pathogenesis of type 2 diabetes mellitus. *Archives of Medical Research.*

0258-8

64. Mostafa T, Wiggins RD. The impact of attrition and non-response in birth cohort studies: a need to incorporate missingness strategies. *Longit Life Course Stud.* 2015;6: 131-146. doi:10.14301/lcs.v6i2.312

cohort, age at follow-up, ethnicity, birth weight, childhood social class and obesity severity): using blood pressure at 43 years in NSHD

S10 Table: Association between ever obese and c

Table 1 Descriptive statistics for life course obesity parameters and cardiometabolic disease risk factors at the biomedical sweep of those in target study sample (n=20 746)

		<i>NSHD 1946 (n=2968)</i>	<i>1958 NCDS (n=9302)</i>	<i>1970 BCS (n=8476)</i>
Sex				
<i>Males</i>	n (%)	1459 (49.2)	4630 (49.8)	4106 (48.4)
<i>Females</i>	n (%)	1509 (50.8)	4672 (50.2)	4370 (51.6)

Age at follow up (years)	mean (SD)	-	53.5 (0.2)	-	45.2 (0.4)	-	47.3 (0.7)
BMI at follow-up (kg/m ²)	median (IQR)	1.3	26.6 (24.2; 29.9)	1.3	26.6 (24.0; 29.9)	13.4	27.6 (24.6; 31.5)
Obese at follow-up (BMI>30kg/m ²)	n (%)	1.3	707 (24.1)	1.3	2239 (24.4)	13.4	2424 (33.0)
Systolic blood pressure (mmHg)*	mean (SD)	1.9	136.0 (20.1)	0.5	126.5 (16.5)	11.5	124.6 (15.2)
Diastolic blood pressure (mmHg)*	mean (SD)	1.9	84.4 (12.2)	0.5	78.8 (10.8)	11.5	

Figure legends:

Fig 1: Example obesity traits (onset, duration and severity (area-under-the curve and above obesity cut-off)) derived from the BMI-z-score trajectories of two random participants




Fig 2: Association between ever obese and categories of obesity duration (vs never obese) and HbA1c (left panel) and risk for elevated HbA1c (right panel)



Fig 3: Association between ever obese and categories of obesity duration (vs never obese) and SBP, DBP and HDL-C




Fig 4: Association between ever obese and categories of obesity duration (vs never obese) and risk for hypertension and low HDL-cholesterol